What question did this study set out to answer?

To review the clinical safety, efficacy, and controversial off-label application of low molecular weight heparins for managing placenta-mediated complications during pregnancy.

September 9, 2021Obstetrics Gynecology and ReproductionOpen Access

Advisory Board conclusion following the discussion "Controversial issues of low molecular weight heparins use in obstetrics"

Q: What is the clinical evidence from this study?

Study design: Review. Population: Pregnancy with increased risk of placenta-mediated complications. Intervention: Low molecular weight heparins (LMWHs). Primary outcome: Effectiveness and safety (foetal and maternal complications).

View Full Paper

Ask AI

Bookmark

Key result

LMWH is linked to low maternal and fetal complications in pregnancies at risk for placenta-mediated events.

Why the study?

Low molecular weight heparins have off-label status for placenta-mediated complications, prompting an evaluation of their effectiveness and safety in pregnant women at increased risk.

Are low molecular weight heparins effective and safe in pregnant women at an increased risk of placenta-mediated complications?

Population

Pregnant women at an increased risk of placenta-mediated complications

Design

Review

Authors

AEArticle EditorialRussian Academy of Sciences

Discussion

Member takes

Implication

May support LMWH consideration in high-risk pregnancies; leaves open need for RCTs to confirm efficacy.

Key Points

To review the clinical safety, efficacy, and controversial off-label application of low molecular weight heparins for managing placenta-mediated complications during pregnancy.
Conducted an advisory board review synthesizing clinical evidence on antithrombotic management in obstetrics.
Evaluated maternal and fetal outcomes linked to low molecular weight heparins versus unfractionated heparin in high-risk pregnancies.
Low molecular weight heparins largely replace unfractionated heparin due to superior ease of administration and proven anticoagulant efficacy.
Therapy is associated with a low incidence of fetal and maternal adverse events, supporting safety despite its off-label regulatory status for placental complications.

Structured PICO

Are low molecular weight heparins effective and safe in pregnant women at an increased risk of placenta-mediated complications?

Population

Pregnant women at an increased risk of placenta-mediated complications

Intervention

Low molecular weight heparins (LMWHs)

Outcome

Effectiveness and safety (incidence of foetal and maternal complications)

LMWHs are considered effective and safe for use in pregnant women at risk of placenta-mediated complications, despite their off-label status.

Cite This Study

Article Editorial (2021) conducted a review in Pregnancy with increased risk of placenta-mediated complications. Low molecular weight heparins (LMWHs) was evaluated on Effectiveness and safety (foetal and maternal complications). Low molecular weight heparins are effective, safe, and associated with a low incidence of foetal and maternal complications in pregnant women at risk of placenta-mediated complications.

synapsesocial.com/papers/6a10df9bcfa01e990d9fb64b https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.244

View Full Paper

Ask AI

Bookmark

Advisory Board conclusion following the discussion "Controversial issues of low molecular weight heparins use in obstetrics"

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Advisory Board conclusion following the discussion "Controversial issues of low molecular weight heparins use in obstetrics"

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider